Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04411433
Recruitment Status : Recruiting
First Posted : June 2, 2020
Last Update Posted : June 2, 2020
Sponsor:
Collaborators:
Hacettepe University, Faculty of Medicine
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Umraniye Education and Research Hospital
SB Istanbul Education and Research Hospital
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Tepecik Training and Research Hospital
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine
Ankara University
Ankara City Hospital Bilkent
Ankara Training and Research Hospital
Ege University Hospital (Application and Research Center)
Kocaeli Derince Education and Research Hospital
Istanbul University, Istanbul Faculty of Medicine
Kayseri City Hospital
Information provided by (Responsible Party):
Prof. Ates KARA, MD, Hacettepe University

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 30, 2020
Estimated Study Completion Date : July 30, 2020